Median CgA levels in patients with NETs (n = 57), non-NET pancreatic tumors (n = 12), and prostate cancer (n = 16) were 1.74 log ng/mL (interquartile range (IQR): 0.87 log ng/mL), 1.75 log ng/mL (IQR: 0.44 log ng/mL), and 1.80 log ng/mL (IQR: 0.29 log ng/mL), respectively (Figure 2). This evidence concerns the gene CGA and prostate cancer.